The Association for the Accreditation of Human Research Protection Programs, or AAHRPP as it's known, has issued a final version of its first major revisions to its standards, which are now eight years old. The process began in late 2008 and included a comprehensive review of the standards as well as a period for public comment. The result is a reduction in standards, from 22 to 15, and a reduction in the number of elements, from 77 to 60.
An AAHRPP press release describes the revisions as "providing a more logical framework for a human research protection program (HRPP) and better definition of the primary roles and responsibilities of the entities that comprise an HRPP."
It also says that the revised version allows for more flexibility in interpreting the standards and strengthens the standards on global research, conflict of interest, community-based research, and data and safety monitoring.
Starting March 1, 2010, organizations interested in applying for accredidation will follow the final revised accreditation standards, which will then be referred to as the AAHRPP Accreditation Standards. But from now until February 28, 2010, organizations may follow either the revised standards or the pre-revised accreditation standards.
Those interested in checking out the revised standards or comparing them with the current standards can do so at AAHRPP's Web site.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.